Aims Insulin therapy is indicated for people with Type 1 diabetes mellitus; however, treatment-related weight gain and hypoglycaemia represent barriers to optimal glycaemic management. This study assessed the health economic value of maintained reductions in HbA 1c , BMI and hypoglycaemia incidence among the UK Type 1 diabetes population.
Introduction
Type 1 diabetes mellitus is a chronic autoimmune disorder associated with significant morbidity and mortality, and an estimated loss in life expectancy of 11-13 years among young adults in the United Kingdom (UK) [1] . The management of the condition and its long-term complications impose significant direct costs on the National Health Service (NHS), and its societal burden is associated with additional indirect costs. While Type 1 diabetes affected 400 000 individuals in the UK during 2010-2011, recent projections suggest that Type 1 diabetes prevalence will rise to 652 000 individuals by [2035] [2036] , and the economic burden of the condition will grow accordingly [2] . Between 2010-2011 and 2035-2036, the direct healthcare costs of Type 1 diabetes are predicted to rise from £1.0 billion to £1.8 billion, with indirect costs of Type 1 diabetes-related morbidity and mortality predicted to rise from £900 million to £2.4 billion during the same period [2] .
Micro-and macrovascular complications account for approximately 70% of NHS expenditure on Type 1 diabetes management [2] . These include potentially avoidable complications that arise as a consequence of poor glycaemic control; thus, improved disease management may produce significant cost savings for the UK public healthcare system. Treatment regimens that mimic physiological insulin secretion serve to control HbA 1c levels in people with Type 1 diabetes, with a view to preventing the long-term health complications associated with the condition. However, exogenous insulin is often associated with weight gain and the incidence of hypoglycaemic events, which in turn are barriers to optimal glycaemic management [3, 4] . Updated guidance from the National Institute for Health and Care Excellence (NICE) recommend insulin therapy in combination with diet and lifestyle changes for the management of Type 1 diabetes, which collectively aim to normalize HbA 1c levels, control weight and minimize cardiovascular risk factors [5] .
Although NICE guidance published in 2004 recommended that Type 1 diabetes therapy should aim to reduce HbA 1c levels to < 59 mmol/mol (7.5%), the 2015-2016 National Diabetes Audit found that 71% of people with Type 1 diabetes in England and Wales failed to achieve and maintain this goal [6] . Since 2015, NICE guidelines now recommend that adults with Type 1 diabetes aim for a target HbA 1c of 48 mmol/mol (6.5%) or below [5] ; a level of glycaemic control that only 8% currently reach [6] . Despite the difficulty faced by individuals and their clinicians to achieve a stricter treatment target, health economic modelling has recently demonstrated the value of making modest, incremental improvements to glycaemic control in Type 1 diabetes. Based on current UK population data, it was estimated that an achievable HbA 1c reduction of 4 mmol/ mol (0.4%) could avoid 81 000 microvascular and 7000 macrovascular events over 25 years [7] . Fewer complications were subsequently associated with per-person cost savings between £2057 and £4136 over 25 years, which equated to a potential cost avoidance of £995 million for the total UK population [7] . Importantly, the economic impact of differing levels of glycaemic control, in addition to treatment effects, on individual outcomes and quality of life remain poorly characterized.
With this in mind, the aim of this study was to quantify the health economic burden of elevated HbA 1c , BMI and frequency of hypoglycaemic events in people with Type 1 diabetes, expressed in terms of costs, life-years and qualityadjusted life-years (QALYs) at a per-person and national level. The cost savings and QALY gains associated with incremental, maintained reductions in HbA 1c , BMI and hypoglycaemia incidence were subsequently estimated, and the net monetary benefit associated with improved Type 1 diabetes management was derived.
Methods

The Cardiff Type 1 Diabetes Model
The Cardiff Type 1 Diabetes Model has been described in detail previously [8] . In brief, it is a fixed-time-increment stochastic microsimulation model designed to evaluate the lifetime impact of therapeutic changes for individuals with Type 1 diabetes. Consistent with both established and recently published Type 1 diabetes models [9] , risk equations implemented within the Cardiff Type 1 Diabetes Model were adapted to incorporate long-term epidemiological evidence derived from the Diabetes Control and Complications Trial (DCCT) [10] and follow-up study (Epidemiology of Diabetes Interventions and Complications; EDIC) [11] , in addition to cardiovascular risk equations from the Swedish National Diabetes Registry [12] . A flow diagram of the Cardiff Type 1 Diabetes Model is shown in Fig. S1 ; approaches to simulate Type 1 diabetes-related complications within the model are summarized in Table S1 . Further details regarding the development and validation of the Cardiff Type 1 Diabetes Model are provided in its original publication [8] .
Costs and utilities
The direct costs of managing Type 1 diabetes and its complications were implemented within the Cardiff Type 1 Diabetes Model. The occurrence of diabetes-related events was associated with a reduction in quality of life; the utility decrements applied (additively) were consistent with the default values of the CORE Diabetes Model [13] and those applied in recent guidelines [5] . Further details regarding the costs and utilities applied in the model are provided in Tables  S2-S4 . The utility decrement associated with hypoglycaemia was modelled using regression equations that linked event frequency and severity to utility, via the fear of hypoglycaemia score [14] .
Baseline characteristics and time-dependent risk factors
Two characteristic profiles were modelled, representing an average person with Type 1 diabetes in the UK ('average UK profile') and a more recently diagnosed individual ('younger
What's new?
• This study demonstrated the burden of inadequate Type 1 diabetes management, and quantified the value of reducing HbA 1c , weight and hypoglycaemia frequency among the UK Type 1 diabetes population.
• Significant cost savings, quality-adjusted life-year gains and net monetary benefit were predicted in those who achieve HbA 1c targets recommended in national guidelines; nevertheless, any incremental improvement in glycaemic management substantially reduced the burden of Type 1 diabetes mellitus on individuals and healthcare systems.
• Given the influence of weight and hypoglycaemia on health economic outcomes, these factors should also be key considerations when assessing the value of Type 1 diabetes technologies.
UK profile'), consistent with those reported in NICE guideline NG17 [5] ( The total diabetes population (comprising people with Type 1 and Type 2 diabetes) was estimated using 2015 diabetes prevalence data for England [20] , Wales [21] , Scotland [22] and Northern Ireland [23] . The Type 1 diabetes population (approximately 10% of all people with diabetes [20, 22] ) was stratified into the four HbA 1c categories, according to distributions reported by the National Diabetes Audit 2014-2015 [24] .
Results
Value of improved glycaemic control Figure 1 demonstrates the impact of reducing HbA 1c from 86 mmol/mol (10.0%) to 42 mmol/mol (6.0%) on perperson costs, life-years and QALYs. An average UK person with Type 1 diabetes and an HbA 1c of 86 mmol/mol (10.0%) was expected to cost a discounted total of £23 795 over a lifetime. Lowering HbA 1c from 86 mmol/mol (10.0%) to 42 mmol/mol (6.0%) in 11 mmol/mol (1.0%) increments was associated with gross cost savings of £3746, £3538, £2983 and £2382 (totalling £12 649). Predicted cost savings were attributed to the avoidance of diabetes-related complications; a breakdown of discounted per-person costs are provided in Fig. S2 . For a unit reduction in HbA 1c from 86 mmol/mol (10.0%) to 75 mmol/mol (9.0%), predicted cost savings were largely driven by reduced costs of neuropathy (À£2492; À66.5%), retinopathy (À£901; À24.1%) and nephropathy (À£503; À13.4%), while some additional costs were incurred for severe hypoglycaemia (+£121; +3.2%), cardiovascular disease (+£17; +0.4%) and ketoacidosis (+£13; +0.3%). Despite overall cost savings, monetized QALY gains were the major driver of NMB associated with improved glycaemic control. Lowering HbA 1c from 86 mmol/mol (10.0%) to 42 mmol/mol (6.0%) in 11 mmol/mol (1.0%) units led to incremental QALY gains of 0.84, 0.77, 0.66 and 0.53 (totalling 2.80); and associated NMB of £20 518, £18 935, £16 175 and £12 993 (totalling £68 621), respectively.
Estimated costs increased for a more recently diagnosed individual. A person with a 'younger UK profile' and an HbA 1c of 86 mmol/mol (10.0%) was estimated to incur a total discounted lifetime cost of £23 739. Gross cost savings when HbA 1c was reduced from 86 mmol/mol (10.0%) to 42 mmol/mol (6.0%) in 11 mmol/mol (1.0%) increments were estimated to be £4772, £4394, £3634 and £2800 (totalling £15 601). Predicted cost savings were similarly attributed to the avoidance of adverse events; a breakdown of discounted per-person costs are provided in Fig. S3 . For a unit reduction in HbA 1c from 86 mmol/mol (10.0%) to 75 mmol/mol (9.0%), the majority of cost savings were related to the reduced costs of neuropathy (À£2871; À63.9%), nephropathy (À£1260; À28.1%) and retinopathy (À£855; À19.0%), while some additional costs were incurred for ketoacidosis (+£381; +8.5%) and cardiovascular disease (+£113; +2.5%). However, the predicted value of improved glycaemic control was largely driven by mon- 
Value of reduced frequency of hypoglycaemia
In people experiencing no more than 10 non-severe hypoglycaemic events, one fewer event was associated with oneyear QALY gains ranging between 0.001 (reduction from 10 to nine events) and 0.01 (reduction from one to zero events). As no costs were applied to the incidence of nonsevere hypoglycaemia in this study, the predicted value of reduced event frequency was driven entirely by monetized QALY gains. Thus, at a willingness-to-pay threshold of £20 000 per QALY, one fewer non-severe event equated to incremental NMB ranging between £27 and £197 (Fig. 2) . If modelled reductions in non-severe hypoglycaemia frequency were maintained in an average UK person with HbA 1c of 75 mmol/mol (9.0%), this would translate to lifetime QALY gains of between 0.023 (reduction from 10 to nine events) and 0.164 (reduction from one to zero events), and associated incremental NMB of £452-£3289. In people experiencing 20-100 non-severe hypoglycaemia events, 10 fewer events resulted in one-year QALY gains ranging between 0.001 (reduction from 100 to 90 events) and 0.009 (reduction from 20 to 10 events), and associated incremental NMB of £30-£183 (Fig. 2) . If modelled reductions in non-severe hypoglycaemia frequency were maintained in an average UK person with HbA 1c of 75 mmol/mol (9.0%), this would translate to lifetime QALY gains of between 0.025 (reduction from 100 to 90 events) and 0.153 (reduction from 20 to 10 events), and associated incremental NMB of £495-£3068.
In people with no more than five severe hypoglycaemic events, the per-person cost saving was £344 for every severe hypoglycaemic event avoided. Complete avoidance of severe hypoglycaemia was associated with a 0.01 QALY gain over one year; thus, incremental NMB ranged between £544 (reduction from one to zero events) and £1921 (reduction from five to zero events) (Fig. S7) . In an average UK person with HbA 1c of 75 mmol/mol (9.0%), maintained avoidance of severe hypoglycaemia over a lifetime would translate to 0.167 QALYs gained, and incremental NMB between £9104 (reduction from one to zero events) and £32 136 (reduction from five to zero events).
Value of reduced BMI
Costs associated with weight change were not applied in model analyses; thus, the predicted value of reduced BMI was driven entirely by monetized utility gains. Reducing BMI by 1 kg/m 2 was associated with a 0.006 QALY gain over one year, which corresponded to an incremental NMB of £120 for each unit reduction in BMI. Therefore, reducing BMI from 35 kg/m 2 to 25 kg/m 2 equated to an incremental NMB of £1200 per year, at a willingness-to-pay threshold of £20 000 per QALY. If modelled weight change was maintained in an average UK person with HbA 1c of 75 mmol/mol (9.0%), each unit reduction in BMI would translate to a lifetime QALY gain of 0.100, and associated incremental NMB of £2007.
Discussion
Recent studies have reported the health economic value of improved disease management in Type 2 diabetes [25] , and estimated the potential costs avoided that a modest HbA 1c reduction would achieve within the UK healthcare system [7] . In the present analysis, we quantified the health FIGURE 2 Discounted value of reduced non-severe hypoglycaemic event incidence in people with Type 1 diabetes (net monetary benefit at £20 000 per quality-adjusted life-year gained). [5] , and the present study highlighted the considerable health economic benefits that could be achieved in those who successfully reach and maintain this 'ideal' HbA 1c target. However, NICE additionally recognize that several factors, including comorbidities, risk of complications and history of hypoglycaemia, represent barriers to achieving optimal glycaemic control; and subsequently advocate the use of individualized HbA 1c targets in these cases [5] . With this in mind, we demonstrated that unit reductions in HbA 1c were associated with substantial per-person cost savings, and gains in life-years and QALYs, regardless of whether NICE treatment targets were met. The feasibility of realizing such benefits is highly individualized; nevertheless, the results of this study support the notion that incremental improvements in glycaemic control, in addition to BMI and hypoglycaemia incidence, can potentially alleviate the burden of Type 1 diabetes on individuals and healthcare systems. Analyses were conducted independent of pharmacological management and service delivery costs; and it is likely that strategies to improve glycaemic control, hypoglycaemia event rate and/ or body weight will incur additional costs to the NHS. However, if this expenditure falls below the predictions of NMB generated in this study, such interventions would be deemed cost-effective at a willingness-to-pay threshold of £20 000 per additional QALY gained.
People with Type 1 diabetes who experience poor glucose control, high BMI and a high frequency of hypoglycaemia have the greatest risk of adverse clinical outcomes, health disutility and potential resource use. Indeed, previous estimates have indicated that a modest reduction in HbA 1c (4 mmol/mol; 0.4%) among people with Type 1 diabetes and HbA 1c exceeding 75 mmol/mol (9.0%) may save the NHS £447 million over 25 years [7] . Our results additionally illustrate that people with higher baseline HbA 1c have the potential to achieve relatively greater QALY gains with improved glycaemic control, while reducing weight and avoiding hypoglycaemia in those with high BMI and hypoglycaemia event rates, respectively, was associated with increasing NMB. Improved population-based intervention strategies that target such 'high risk' individuals may therefore provide the greatest clinical and financial benefits to the healthcare system. However, intervention-specific research is required to assess the feasibility of improving HbA 1c , BMI and/or hypoglycaemia frequency in those with poorly managed Type 1 diabetes, and the resource and health system implications of realizing these targets in such a challenging population.
Injectable basal insulin therapies for Type 1 diabetes currently include intermediate-acting [neutral protamine Hagedorn (NPH) insulin], long-acting (glargine and detemir analogues) and ultra-long-acting (degludec analogue) agents. Based on evidence that multiple daily insulin injections using long-acting analogues are more efficacious than NPH insulin in Type 1 diabetes, current NICE guidelines recommend twice-daily insulin detemir as the optimal basal treatment regimen [5] . In those who fail to maintain HbA 1c below 69 mmol/mol (8.5%) or experience disabling hypoglycaemia following multiple daily insulin injections, rapid-acting agents (aspart, glulisine and lispro analogues), delivered using continuous subcutaneous insulin infusion devices, are subsequently advocated [26] . Guideline recommendations are partly founded on cost-utility analyses; however, insulin therapy is highly individualized, and drawing direct comparisons between Type 1 diabetes technologies poses several methodological challenges. For example, insulin titration algorithms and levels of care are heterogeneous across studies and not reflective of routine clinical practice [27] ; and the reporting of hypoglycaemic events in clinical trials is often confounded by ill-defined HbA 1c thresholds and nocturnal periods [28] . Our study illustrates the value of reducing HbA 1c , hypoglycaemia and body weight irrespective of treatment strategy; therefore, data describing these factors are useful to inform cost-effectiveness analyses for any therapeutic modality in Type 1 diabetes.
In light of this, the present study used an outcome-focused approach to quantify the health economic value of improving HbA 1c , reducing the frequency of hypoglycaemic events and lowering BMI in people with Type 1 diabetes, regardless of the intervention used to achieve these responses. Our results do not support the adoption of any particular therapeutic strategy, but rather support the notion that modest improvements to Type 1 diabetes management can reduce the clinical and financial burdens associated with developing and managing its long-term health complications. This may be achieved through the use of insulin-based therapies; however, weight gain and hypoglycaemia are common adverse events and barriers to optimal glycaemic control [3 4] . In line with current NICE guidance, promoting lifestyle changes and educational tools, including the dose-adjustment for normal eating programme, will additionally assist in managing Type 1 diabetes and its complications [5] . Emerging adjunctive therapies, that serve to improve glycaemic control whilst reducing insulin-related side effects, are currently under investigation and may provide significant health economic value in the future [29] . [32] . By simulating disease progression over a time horizon longer than that feasible in clinical trials, computer modelling represents an important tool to quantify the long-term health economic outcomes of Type 1 diabetes interventions, and support clinical and reimbursement decision-making [9] . In this study, the value of modest improvements in disease management was quantified using the Cardiff Type 1 Diabetes Model, implemented with risk equations partially derived from DCCT/EDIC study data [10] . Model validity is contingent on the data used to inform its development; therefore, caution is required when extrapolating model predictions beyond the scope of DCCT/EDIC observations. However, several baseline characteristics act as predictive risk factors within the Cardiff Type 1 Diabetes Model (including age, gender, age at diabetes onset, HbA 1c and weight); and the accuracy and generalizability of its outputs have previously been validated against other new and established Type 1 diabetes models [8] . Subsequently, this model represents a plausible approach to assess the value of improving glycaemic control, hypoglycaemia incidence and body weight in populations not reflective of the DCCT/EDIC study cohort, such as those over 60 years of age, or with a long duration of Type 1 diabetes. Furthermore, the impact of weight, hypoglycaemia and HbA 1c on predicted QALYs in this study are consistent with published analyses using the Cardiff Type 2 Diabetes Model [25] ; and the structure and performance of both Cardiff models have undergone rigorous scrutiny at several Mount Hood Diabetes Challenge Meetings [33] [34] [35] .
Our study demonstrated the individual impact of HbA 1c , weight and hypoglycaemia on health economic outcomes in people with Type 1 diabetes, with all other parameters held constant. Clinically, there is a well-recognized relationship between glycaemic control, weight and hypoglycaemia in Type 1 diabetes, and the assessment of each factor in isolation subsequently represents one limitation of this analysis. However, the objective of this study was to demonstrate the independent benefits of reducing HbA 1c , BMI and hypoglycaemia incidence, and as such, aims to provide clinicians and payers with evidence to quantify the health economic value of improving each factor, both individually and in combination. Although the value of lowering HbA 1c was evaluated over a lifetime, BMI and frequency of hypoglycaemia were assessed in the short-term due to the duration over which such changes may be observed, and the relative delays in the observed impact of each factor on individual outcomes. Nevertheless, QALY gains, cost savings and/or NMB predicted over one year were scaled to illustrate the benefits of managing BMI and hypoglycaemia over a lifetime, in an average UK person with Type 1 diabetes. Furthermore, the impact of BMI and hypoglycaemia on the risk of adverse events including falls and fractures, cardiovascular disease and all-cause mortality, and their correlation with other risk factors related to Type 1 diabetes, were not considered [36] [37] [38] . Although these modelling assumptions may collectively underestimate the true, long-term value of lowering BMI and hypoglycaemic event incidence in people with Type 1 diabetes, our study nevertheless demonstrates the impact of weight and hypoglycaemia on health-related quality of life, to which a monetary value has been derived.
Due to the UK payer perspective adopted in the study, societal costs were not quantified, and the strength of the national level estimates reported is contingent on the quality of prevalence data available in the UK. This study did not account for changes in population size since 2015, people with Type 1 diabetes below 17 years of age, nor adjust for Quality and Outcomes Framework disease register estimates in Wales. Cumulatively, these factors may underestimate the true size of the UK Type 1 diabetes population, and therefore the true value associated with improved disease management. The UK perspective of this study may limit the relevance of its economic results to other national settings; however, predicted health utility changes are generalizable, and may be used in conjunction with country-specific cost data to inform local decisionmaking.
In conclusion, this study highlighted the health economic benefits of incremental improvements to HbA 1c , BMI and hypoglycaemic event frequency in the UK Type 1 diabetes population. Model analyses found that monetized QALY gains were the major driver of NMB associated with improved Type 1 diabetes management, while predicted cost savings were attributed to the avoidance of its long-term health complications. Given the influence of weight and hypoglycaemia on health economic outcomes in Type 1 diabetes, these factors must be key considerations when assessing the cost-effectiveness of health technologies and their efficacy in clinical practice.
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